Literature DB >> 34036395

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.

Beige Zong1, Lu Sun1, Yang Peng1, Yihua Wang1, Yu Yu2, Jinwei Lei1, Yingzi Zhang1, Shipeng Guo3, Kang Li1, Shengchun Liu1.   

Abstract

HORMA domain‑containing protein 1 (HORMAD1), is normally expressed only in the germline, but is frequently re‑activated in human triple‑negative breast cancer (TNBC); however, its function in TNBC is largely unknown. In the present study, the expression and biological significance of HORMAD1 in human TNBC was evaluated. Bioinformatics analysis and reverse transcription‑quantitative PCR were used to evaluate HORMAD1 expression in datasets and cell lines. HORMAD1 protein expression was detected in TNBC samples using immunohistochemical assays, and the effect of HORMAD1 on cell proliferation was determined using Cell Counting Kit‑8, plate colony formation and standard growth curve assays. Cell cycle, reactive oxygen species (ROS) and apoptosis analyses were conducted using flow cytometry. The activity of caspases was measured using caspase activity assay kit. The levels of key apoptosis regulators and autophagy markers were detected by western blot analysis. TNBC cell survival and apoptosis were not influenced by small interfering RNA targeting HORMAD1 alone; however, HORMAD1 knockdown enhanced autophagy and docetaxel (Doc)‑induced apoptosis, compared with the control group. Furthermore, higher ROS levels and caspase‑3, ‑8 and ‑9 activity were detected in MDA‑MB‑436 TNBC cells with HORMAD1 knockdown upon exposure to Doc. The levels of the induced DNA damage marker γH2AX were also higher, while those of the DNA repair protein RAD51 were lower in TNBC cells with HORMAD1 knockdown compared with the controls. Furthermore, the expression of the autophagy marker P62 was enhanced in MDA‑MB‑231 cells in response to HORMAD1 overexpression. Notably, Doc‑induced apoptosis was similarly increased by both HORMAD1 overexpression and treatment with the autophagy inhibitor, 3‑methyladenine (3MA); however, the Doc‑induced increase in autophagy was not inhibited by 3MA. The present data indicated that HORMAD1 was involved in autophagy and that the inhibition of autophagy can partially enhance the induction of apoptosis by Doc. The role of HORMAD1 in the DNA damage tolerance of tumor cells may be the main reason for Doc resistance; hence, HORMAD1 could be an important therapeutic target in TNBC.

Entities:  

Keywords:  DNA damage; HORMA domain‑­containing protein 1; apoptosis; autophagy; triple‑negative breast cancer

Year:  2021        PMID: 34036395     DOI: 10.3892/or.2021.8089

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  The cancer/testis antigen HORMAD1 mediates epithelial-mesenchymal transition to promote tumor growth and metastasis by activating the Wnt/β-catenin signaling pathway in lung cancer.

Authors:  Kang Liu; Li Cheng; Kun Zhu; Jinhu Wang; Qiang Shu
Journal:  Cell Death Discov       Date:  2022-03-28

2.  A maternal high-fat diet induces fetal origins of NASH-HCC in mice.

Authors:  Takao Takiyama; Toshihiro Sera; Masanori Nakamura; Masato Hoshino; Kentaro Uesugi; Shin-Ichi Horike; Makiko Meguro-Horike; Ryoichi Bessho; Yuri Takiyama; Hiroya Kitsunai; Yasutaka Takeda; Kazuki Sawamoto; Naoto Yagi; Yuji Nishikawa; Yumi Takiyama
Journal:  Sci Rep       Date:  2022-07-30       Impact factor: 4.996

3.  DNA Damage Repair Classifier Defines Distinct Groups in Hepatocellular Carcinoma.

Authors:  Markia A Smith; Sarah C Van Alsten; Andrea Walens; Jeffrey S Damrauer; Ugwuji N Maduekwe; Russell R Broaddus; Michael I Love; Melissa A Troester; Katherine A Hoadley
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

4.  Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer.

Authors:  Rassanee Bissanum; Rawikant Kamolphiwong; Raphatphorn Navakanitworakul; Kanyanatt Kanokwiroon
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.